...

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >A phase 1/2 study evaluating the safety, pharmacokinetics and efficacy of ABT-414 in subjects with advanced solid tumors likely to over-express the epidermal growth factor receptor (EGFR)

【24h】

A phase 1/2 study evaluating the safety, pharmacokinetics and efficacy of ABT-414 in subjects with advanced solid tumors likely to over-express the epidermal growth factor receptor (EGFR)

机译：1/2期研究评估了ABT-414在患有可能过度表达表皮生长因子受体（EGFR）的晚期实体瘤患者中的安全性，药代动力学和功效

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2014年第6期|共1页
作者
Tolcher A.; Goss G.; Gordon M.; Gandhi L.; Papadopoulos K. P.; Rasco D.; Pedersen M.; Fischer J.; Ames W.; Xiong H.; Dudley M.; Munasinghe W.; Ansell P.; Holen K.; Vokes E.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A phase 1/2 study evaluating the safety, pharmacokinetics and efficacy of ABT-414 in subjects with advanced solid tumors likely to over-express the epidermal growth factor receptor (EGFR) [J] . Tolcher A., Goss G., Gordon M., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第Suppla6期

机译：1/2期研究评估了ABT-414在患有可能过度表达表皮生长因子受体（EGFR）的晚期实体瘤患者中的安全性，药代动力学和功效
2. Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR [J] . Sharma Shringi, Mittapalli Rajendar K., Holen Kyle D., Clinical pharmacokinetics . 2015,第10期

机译：ABT-806的人口药代动力学，一种研究抗表皮生长因子受体（EGFR）单克隆抗体，其在可能过度高表达野生型EGFR或Expressiant III突变体EGFR中
3. 198 POSTER Multi-targeted inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways: a phase I study of cetuxiamb (C), erlotinib (E), and bevacizumab (B) in patients with solid tumors [J] . C.Lin, G.Preston, E.Calvo, European Journal of Cancer Supplements . 2006,第12期

机译：198 POSTER多靶点抑制表皮生长因子受体（EGFR）和血管内皮生长因子受体（VEGFR）途径：头孢曲松（C），厄洛替尼（E）和贝伐单抗（B）的I期研究肿瘤
4. QSAR Study of Quinazoline Derivatives as Inhibitor of Epidermal Growth Factor Receptor-Tyrosine Kinase (EGFR-TK) [C] . La Ode Aman, Widisusanti Abdulkadir, Julitha Geybie Rembet, International Conference on Computation for Science and Technology . 2015

机译：喹唑啉衍生物作为表皮生长因子受体 - 酪氨酸激酶（EGFR-TK）抑制剂的QSAR研究
5. Epidermal growth factor receptor (EGFR) mutations and tumor-specific targeting of malignant glioma by vaccine-based immunotherapeutic approaches. [D] . Ciesielski, Michael John. 2003

机译：表皮生长因子受体（EGFR）突变和恶性神经胶质瘤的肿瘤特异性靶向通过基于疫苗的免疫治疗方法。
6. Phase I and pharmacokinetic study of dacomitinib (PF-00299804) an oral irreversible small molecule inhibitor of human epidermal growth factor receptor-1 -2 and -4 tyrosine kinases in Japanese patients with advanced solid tumors [O] . Toshiaki Takahashi, Narikazu Boku, Haruyasu Murakami, -1

机译：达可替尼（PF-00299804）的I期和药代动力学研究它是一种口服不可逆的人类表皮生长因子受体-1-2和-4酪氨酸激酶的小分子抑制剂用于患有晚期实体瘤的日本患者
7. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors [O] . 2012

机译：达可替尼（PF-00299804）的I期和药代动力学研究，它是一种口服不可逆的人类表皮生长因子受体-1，-2和-4酪氨酸激酶的小分子抑制剂，用于患有晚期实体瘤的日本患者

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号